8.37
0.33 (4.10%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Alumis Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.21% |
| % Held by Institutions | 74.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 30 Sep 2024 | 10,645,965 |
| Foresite Capital Management V, Llc | 30 Sep 2024 | 5,584,889 |
| Samsara Biocapital, Llc | 30 Sep 2024 | 3,266,498 |
| Nextech Invest Ltd. | 30 Sep 2024 | 1,476,998 |
| Yu Fan | 30 Sep 2024 | 789,618 |
| Omega Fund Management, Llc | 30 Sep 2024 | 653,223 |
| Ally Bridge Group (Ny) Llc | 30 Sep 2024 | 418,416 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (HC Wainwright & Co., 210.63%) | Buy |
| Median | 25.50 (204.66%) | |
| Low | 25.00 (Baird, 198.69%) | Buy |
| Average | 25.50 (204.66%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 10.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Dec 2024 | 26.00 (210.63%) | Buy | 8.82 |
| 14 Nov 2024 | 26.00 (210.63%) | Buy | 9.41 | |
| Baird | 31 Oct 2024 | 25.00 (198.69%) | Buy | 11.32 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2024 | Announcement | Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 |
| 14 Nov 2024 | Announcement | Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 |
| 13 Nov 2024 | Announcement | Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements |
| 04 Nov 2024 | Announcement | Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference |
| 27 Sep 2024 | Announcement | Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |